Compare · ARGX vs TVGN
ARGX vs TVGN
Side-by-side comparison of argenx SE (ARGX) and Tevogen Bio Holdings Inc. (TVGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and TVGN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.83B, about 1367.2x TVGN ($46.7M).
- ARGX has been more active in the news (10 items in the past 4 weeks vs 3 for TVGN).
- ARGX has more recent analyst coverage (25 ratings vs 2 for TVGN).
- Company
- argenx SE
- Tevogen Bio Holdings Inc.
- Price
- $1027.61-0.49%
- $6.31-1.41%
- Market cap
- $63.83B
- $46.7M
- 1M return
- +23.71%
- -
- 1Y return
- +45.55%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2022
- News (4w)
- 10
- 3
- Recent ratings
- 25
- 2
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Completes Acquisition of Forte Biosciences, Inc.
- argenx upgraded by UBS with a new price target
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Latest TVGN
- Tevogen Bio Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form S-8 filed by Tevogen Bio Holdings Inc.
- SEC Form 10-Q filed by Tevogen Bio Holdings Inc.
- SEC Form DEF 14A filed by Tevogen Bio Holdings Inc.
- SEC Form 8-K filed by Tevogen Bio Holdings Inc.
- Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
- SEC Form PRE 14A filed by Tevogen Bio Holdings Inc.
- Tevogen Bio Announces 2026 Annual Meeting of Stockholders
- Director Sordillo Victor J. was granted 40,000 shares, increasing direct ownership by 347% to 51,539 units (SEC Form 4)
- Chief Executive Officer Saadi Ryan H. was granted 1,220,000 shares, increasing direct ownership by 49% to 3,705,689 units (SEC Form 4)